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Purpose: To assess the role of diffusion weighted MRI in predicting future responders and
non-responders in breast cancer patients receiving neoadjuvant chemotherapy.
Materials and methods: Thirty-eight breast cancer patients scheduled for NAC between
January 2014 and January 2015 were enrolled in this study. Contrast enhanced MRI and
DWI were performed, where the lesions size and ADC values, were recorded before the
start of NAC, after the first and second cycles and after completion of therapy. The diagnos-
tic performance of morphological (size) and functional (ADC) MRI in predicting early response
and assessing residual disease was then compared to the histopathology.
Results: The percentage change in the ADC values measured before and after the 1st cycle of
NACwas significant, with 79% sensitivity and 95% specificity in predicting tumor response. The
sensitivity and specificity for depicting residual tumor was 94% and 92% respectively for DWI.
Conclusion: DWI is a valuable tool in early identification of responders to NAC in breast cancer
patients, hence selecting patients that will benefit from NAC, avoiding any unnecessary toxi-
city. The accuracy of DWI in detecting residual disease is almost similar to that of CEMRI, act-
ing as a substitute in patients where contrast is contraindicated.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by
Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/4.0/).1. Introduction the past using its potential benefits of better local deliveryThe use of neoadjuvant chemotherapy to treat women
with locally advanced breast cancer has increased overof chemotherapy to the breast via an intact blood supply
before surgical disruption and the ability to evaluate how
lesions respond to the chemotherapy agent via serial imag-
ing before, during, and after therapy (1).
Traditional measurement techniques such as clinical
examination, mammography, or ultrasonography are
imperfect in assessing tumor response to NAC because
tumor size changes often become apparent only after sev-
eral doses of chemotherapy.
The existing literature supports MRI as a method for
assessing tumor response; there is less agreement,
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size of residual tumor after NAC (2).
Through imaging of alterations in the microscopic
motion of water molecules, diffusion weighted Imaging
(DWI) can provide quantitative and qualitative informa-
tion reflecting cellular changes. The apparent diffusion
coefficient (ADC), a quantitative measure that is directly
proportional to the diffusion of water and inversely pro-
portional to the tumor cellular density has been reported
to be useful for characterizing breast tumors (3).
Chemotherapy treatment results in cell lysis and loss of
cell membrane integrity, which results in an increase in
extracellular space and a concomitant increase in diffusion
of water (3). This translates to a rise in the ADC value and
precedes any decrease in tumor size in locally advanced
tumors (4). Based on these effects, DWI can be used to
measure changes in diffusion to detect tumor response.
This would be valuable for individualized tailoring of treat-
ment and would allow for more cost-effective use of
resources (5).
Accurate determination of the transition boundary
between tumor and normal tissue is critical. During con-
servative surgery it is necessary to remove adequate breast
tissue to achieve negative margins and reduce the risk of
local recurrence without compromising the cosmetic out-
come. DWI can be used to predict the involvement of per-
itumor tissues, which could be highly beneficial for
surgical preparation (6).
The present study was designed to address the sensitiv-
ity, specificity and accuracy of DW MRI in evaluating the
tumor response to treatment in particular, the responder
versus the non responder status (correlation of ADC value
changes with the pathological response according to a
standardized classification). This would save the non-
responder patients unnecessary costs and toxicity. Further
study objectives were the depiction of the role of diffusion
imaging in proper delineation of the residual disease
before surgery and hence enhancing the surgical outcomes.
2. Patients and methods
2.1. Patients
Thirty eight patients with histopathologically proven
invasive breast cancer, who were scheduled for NAC in
the time interval between January 2014 and January
2015, were enrolled in this prospective study. In all cases,
breast cancer was diagnosed using true-cut biopsy per-
formed under clinical or sonographic guidance.
All patients were informed by the examinations needed
and the purpose of it and they all agreed.
Exclusion criteria included patients found out to be
metastatic during their work up. Those with known allergy
to the MR contrast medium or impaired renal functions
and Patients with metallic implants or pace makers.
2.2. MRI protocol
2.2.1. MRI technique
Examinations were done using Philips Achieva XR (ram-
pable from 1.5T to 3.0T). A dedicated breast coil was used.The following series were acquired: (1) DWI axial sequence
was performed prior to dynamic images [TR = 5150,
TE = min, frequency-phase 96  96, matrix 96  96, thick-
ness = 4 mm, 0 interval, FOV = 32–34 cm, NEX = 6]. Sensi-
tizing diffusion gradients were applied sequentially in the
x-, y-, and z-directions with b-values of 0, 750 and
1000 s/mm2. (2) Dynamic MR images were sequentially
obtained before and 0, 90, 180, and 270 s after the injection
of 0.1 mmol/kg of body weight of gadopentetate dimeglu-
mine. Axial T2 WI images were obtained with the follow-
ing parameters: TR, 4845.3 ms; TE, 120 ms; NEX, 1; flip
angle, 90; FOV: 355. 6  355. 6 mm; slice thickness,
4.0 mm; and slice interval, 2.0 mm (slice overlap,
2.0 mm). Finally, Dynamic thrive were obtained for con-
trast enhanced images (CE-FS) T1WI. The parameters were
as follows: TR, 7 ms; TE, 3.4 ms; NEX, 1; flip angle, 10;
FOV: 340  340 mm; slice thickness, 2.4 mm.
2.2.2. MRI interpretation
Mammographic study was assessed prior to MRI inter-
pretation. The study design included 4 imaging stages for
each patient: Pre-NAC MRI imaging, during NAC MRI imag-
ing (after 1st and 2nd cycles), and Post-NAC & preoperative
MRI (duration between last MRI and surgery should not
exceed 6 weeks).
Data analysis and interpretation were performed on
Philips Extended MR Work Space eXplore release (EWS)
workstation. We recorded the following data in each of
the 4 aforementioned stages.
2.2.2.1. Morphological data. Longest diameter of: (a)
Enhancing Lesions in CEMRI. (b) Bright Lesions (restricted
diffusion) in DWI.
When edema pattern was found, and where restriction
extended beyond the lesions, we merged views of CE MRI
with ADC maps, to exclude the brightness of T2 shine
through edema.
2.2.2.2. Functional data. ADC values of lesions, with all b
values were used (0, 750, 1000). At this point we merged
views of ADC maps with CE MRI, to define the lesions we
will get ADC values for. In all cases our reference was the
CE MRI, and we measured the ADC values in the corre-
sponding hypointense areas in the ADC map.
Finally, using the Response Evaluation Criteria in Solid
Tumors (RECIST) classification, based on the longest diam-
eter of the target lesion after completion of NAC (3D CE FS
weighted images) to assess treatment response, four
groups were identified (7):
1. Complete response (CR), 2. Partial response (PR), 3.
Progressive disease (PD), 4. Stable disease (SD).
Similarly, using 3 standard deviation criterion, patients
in our study were categorized as responders if their post-
therapy (after fourth cycle), ADC was higher by 3 times the
standard deviation (STD) than the mean pre-therapy ADC.
If the mean ADC was less than 3 STDs, then these patients
were categorized as non-responders. The rationale behind
using the 3 STDs is that it covers 99% of the cases.
Table 3.1
Variable Value
Number of patients 33
Age (Fig. 3.1)
Mean 47.9
Range 25–72
Baseline tumor diameter in CEMRI
Mean 4.7
Range 2–7.8
Baseline ADC
Mean 0.83
Range 0.76–1.12
Surgery
Mastectomy 21
CBS 12
Pathology
IDC 25
ILC 8
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in longest diameter:
1. Objective responders (OR): including CR and PR.
2. Non-responders (NR): including PD and SD.
For each group, we recorded the percentage changes in
ADC values and tumor size before and after the first, sec-
ond and final (fourth) courses of NACT.
After surgery, specimens were evaluated for pathologi-
cal treatment response according to the MD Anderson,
Residual Cancer Burden (RCB) classification.
For data analysis, we defined the ‘‘Responder’’ patients
those having RCB-I&II, and the ‘‘Nonresponder’’ patients
as those having RCB-III (8).
The diagnostic performance of MRI imaging (morpho-
logical and functional imaging) in predicting early
response and assessing residual disease was weighted
against the histopathological results.2.3. Statistical analysis
Data were statistically described in terms frequencies
(number of cases) and percentages when appropriate.
Comparison between the study groups was done using
McNemar test. Agreement was tested using kappa statistic.
Accuracy was represented using the terms sensitivity,
specificity, +ve predictive value, ve predictive value, and
overall accuracy. p values less than 0.05 were considered
statistically significant.
Receiver Operating Characteristic Curve (ROC) analysis
was carried out to determine a suitable cut-off in the per-
centage change in ADC and longest diameter for differenti-
ating responders from non-responders after the first and
second cycles of NACT. The paired Student t test was used
to compare the pre-therapy, post-1st and 2nd cycle thera-
pies mean ADC and longest diameter. A p value less than
0.05 is considered significant.
The k statistic was used to assess the agreement of
residual disease classification between DW imaging and
pathologic findings, as well as between contrast-
enhanced MR imaging and pathologic findings. Pearson’s
correlation coefficient was used to compare imaging mea-
surement methods versus histopathologically determined
tumor size.
All statistical calculations were done using computer
programs SPSS (Statistical Package for the Social Science;
SPSS Inc., Chicago, IL, USA) version 15 for Microsoft
Windows.3. Results
3.1. Characteristics of the population and pathological
response
A total of 38 patients were initially enrolled and under-
went pretreatment MRI. Of these, 2 were excluded as they
had excision surgery of breast lesion before chemotherapy
and 3 did not complete their chemotherapy protocol due to
toxicity. Thus, we had complete data for 33 patients, whichconstituted the final study population. Table 3.1 presents
an overview of patient and tumor characteristics.
All Patients received 4 cycles of preoperative NAC with
FEC 100 (5-fluorouracil, epirubicin and cyclophosphamide)
on day 1, repeated every 21 days. Three patients received 2
more cycles and 4 patients had 16 cycles of Taxane given
on weekly basis after completion of the FEC regimen.
Definitive pathological analysis, according to the MD
Anderson, RCB, showed 6 cases of RCB I (pCR), 10 cases
of RCB II and 17 cases of RCB III, summing up to 16 cases
of responders and 17 cases of NR.3.2. Imaging parameter measurements and predictive ability
A retrospective analysis of the comparison of the per-
centage change in ADC and diameter after 1st, 2nd and
4th NACT between responders and non-responders was
carried out to evaluate the potential of these parameters
in predicting tumor response.
Kappa measurement was run to determine whether
there was agreement between pathological response and
percentage change in ADC as well as in longest diameter
after various cycles of NACT.3.2.1. Percentage change in parameters after first cycle of
chemotherapy
The mean ADC for all patients increased from
0.832  103mm2/s before NACT to 1.109  10 m3 mm2/
s after 1st cycle of NAC (P < .001). However, the mean per-
centage increase in responders (10.72%) was significantly
greater than that in non-responders (3.34%) (P < .001). On
the other hand, there was no significant reduction in the
mean longest diameter of tumors in all patients (respon-
ders & non-responders) after the first cycle of NACT
(P > 0.05) (see Figs. 3.1 and 3.2).
Cut-off value for the percentage change in ADC and
diameter was calculated out to predict tumor response
after 1st cycle of NACT. Analysis of the post-1st cycle NACT
data gave a cut-off value of 9.6% for ADC and 4% for longest
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Fig. 3.1. Graph showing accuracy of % change in longest diameter and
ADC in predicting pathological response after 1st cycle.
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Fig. 3.2. Graph showing significant % change in ADC after 1st and 2nd
cycles of NAC among responders compared to non-responders, while %
change in longest diameter was significant only after 2nd cycle.
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for those cut off values.
3.2.2. Percentage change in parameters after second cycle of
chemotherapy
The mean longest diameter for all patients decreased
from 4.68 cm before NAC to 3.25 cm after the 2nd cycle
of NAC (P < .001). The mean percentage decrease in diam-
eter in responders (28%) was significantly greater than that
in non-responders (15%) (P < .001). Again, there was also
significant increase in the mean ADC of tumors in respon-
ders (22%).
Analysis of the post-II NACT data gave a cut-off value of
15% for ADC and 21% for diameter to differentiate respon-
ders from non-responders. Table 3.3 summarizes the cal-
culated accuracies for those cut off values.Table 3.2
Accuracy of % change of longest diameter and ADC after 1st cycle of NAC in predi
Parameter Sensitivity Specificity
Change in diameter > 4% 10/16 (62.5%) 11/17 (64.7%)
Change in ADC > 9.6% 13/16 (81.25%) 14/17 (82.35%)At this point, our results showed that the change in ADC
soon after the 1st cycle of treatment is statistically signifi-
cant compared to the changes in longest diameter (p value
<0.001), starting to be significant only after the 2nd cycle.
Using the calculated cutoff values, percentage change in
ADC was a better predictive index as early as the 1st cycle
of NAC (sensitivity 81.3%, specificity 83.4%), whereas after
the 2nd cycle percentage change in the longest diameter
was a better predictive index (sensitivity 87.5%, specificity
94.1%) (see Fig. 3.3).
3.2.3. Percentage change in parameters at the end of
chemotherapy
Further, the sensitivity, specificity and p value for MR-
determined response at end of treatment compared with
pathological response were calculated (Table 3.4).
3.3. Morphological and functional Imaging capabilities in
residual disease assessment
As mentioned before, final pathological analysis
revealed 6 cases of pCR and 27 cases of Non-pCR. However,
analysis of our preoperative morphological and functional
data showed 5 cases out of the 33 with pCR and 28 cases
with residual disease (Table 3.5).
The largest diameter of tumor measured by CEMRI at
the end of chemotherapy significantly (p < 0.001) corre-
lated with the largest diameter of residual tumor measured
by pathology. Similarly, there was significant correlation in
the size measurement between DWI and pathological find-
ings (p < 0.001) (Figs. 3.4 and 3.5).
4. Discussion
NAC has a well-established role in the management of
breast cancer. Considering the high toxicity of chemother-
apeutic drugs, early assessment of therapeutic response of
the tumor is essential for patient management. Based on
the treatment response, a second-line therapy or early sur-
gery may be planned for non-responders (9,10).
Traditionally, such assessment has been carried out
through physical examination, mammography, and sonog-
raphy, with suboptimal accuracy in tumor response detec-
tion. Although clinical response is being used as an
indicator of response to chemotherapy, it has many falla-
cies as the fibrosis which occurs following chemotherapy
can be so extensive and give a false impression of increase
in tumor size and on the other side a large tumor which
falsely seems to have responded quite well to chemother-
apy as a result of the resolution of adjacent inflammatory
changes, might still be harboring carcinoma making
patient unfit for breast conserving surgery (10).
The introduction of MRI has improved the diagnostic
accuracy of the response to chemotherapy by measuringcting pathologic response in LABC.
PVP PVN Kappa P value
10/16 (62.5%) 11/17 (64.7%) 0.27 0.12
13/16 (81.25%) 14/17 (82.35%) 0.68 <0.001
Table 3.3
Accuracy of % change of longest diameter and ADC after 2nd cycle of neo-adjuvant chemotherapy by MRI in predicting pathologic response in LABC.
Parameter Sensitivity Specificity PVP PVN Kappa P value
Change in diameter > 21% 14/16 (87.5%) 16/17 (94.1%) 14/15 (93.3%) 16/18 (88.9%) 0.818 <0.001⁄⁄
Change in ADC > 15% 11/16 (66.8%) 13/17 (76.5%) 11/15 (73.3%) 13/18 (72.2%) 0.45 0.01⁄
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Fig. 3.3. Graph showing accuracy of MR response (Post-NACT longest
diameter & ADC) values in detecting pathological response.
Table 3.4
Calculated accuracies of CEMRI and DWI in predicting treatment response
at the end of NAC.
MR Data Pathological response
R NR
Longest diameter
OR 14 4
NR 2 13
Sensitivity: 87.5, specificity:
76.5, PPV: 77.8, NPV: 86.7
ADC
OR (>3SD) 11 3
NR (<3SD) 5 14
Sensitivity: 68.8, specificity:
82.4, PPV: 78.6, NPV: 73.7
Table 3.5
Calculated accuracies of CEMRI and DWI in residual disease assessment.
MR Data Pathological response
Non-pCR pCR
CE-MRI
Non-pCR 24 2
pCR 4 3
Sensitivity: 85.7%, specificity: 60%,
PPV: 92.3%, NPV: 42.8%
DWI
Non-pCR 26 1
pCR 2 4
Sensitivity: 92.8%, specificity: 80%,
PPV: 96.3%, NPV: 66.7%
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these methodologies is the late manifestation of morpho-
logical changes (3).Recent studies have proposed the DWI as a method for
predicting final pathologic response when undertaken
early during NAC in breast cancer. DWI reflects the
thermally driven motion of water molecules in the target
tissue, thus providing information on the intrinsic charac-
teristics of tissue microstructure, which occur before
changes in tumor volume (11,12).
The accurate assessment of residual disease at MR
imaging is crucial. Positive margins following surgery are
associated with an increased long-term risk of recurrence.
Conversely, overexcision of breast tissue can compromise
the patients’ quality of life. Conventional MRI often overes-
timates the residual tumor and does not correlate well
with the histopathological response and DW MR imaging
has been investigated as a means of overcoming such lim-
itations (2,13).
The present study was designed to address the accuracy
of MRI DW in predicting tumor response to treatment early
during the course of therapy. A further objective of this
study was to compare the capability of DW imaging and
CE MR imaging to provide diagnostic information on resid-
ual disease following NAC.
Both the structural (longest diameter) and functional
parameters (ADC) in 33 patients with LABC were obtained
at four time periods (before NACT and after 1st, 2nd and
4th cycles), using 3T conventional MRI and DWI. A retro-
spective analysis of the percentage change in ADC and
diameter was then carried out to determine the capability
of these parameters in predicting the tumor response. Also
the longest diameter of the residual disease at the end of
therapy in CEMRI and DWI was recorded and compared
with histopathological findings.
After 1st cycle of NACT, Our data show that the percent-
age increase in ADC was significantly different in respon-
ders (10.7%) compared with non-responders (3.3%).
However, the mean percentage decrease in diameter was
not significantly different between responders and non-
responders. This suggests the potential of the ADC to dif-
ferentiate non-responders from responders at an early
stage of treatment. After 2nd and 4th cycles of NACT, both
parameters showed significant differences in the percent-
age change between responders and non-responders.
Pickles et al. and Li et al. have reported similar obser-
vations that diffusion changes preceded tumor size
reduction during NACT of breast cancer, and that these
effects could be observed after the first cycle of
chemotherapy (14,15).
After the 1st cycle, our calculated cut off values for the
percentage change in ADC and for longest diameter
resulted in a sensitivity of 81.2% and 62.5% respectively.
The corresponding specificities were 82.4% and 64.7%.
These cut-off values may find applications in the future
for predicting tumor response to therapy.
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of chemotherapy, reported a better sensitivity and speci-
ficity for the calculated ADC cut off values (81% and 88%
respectively) to predict tumor response, over that calcu-
lated for the longest diameter, our study, on the contrary,
showed better results for the longest diameter cutoff val-
ues than that for the ADC. This could be attributed to the
difference in the study design. First of all, they correlated
their findings with the clinical response, while we com-
pared the MR tumor response (both morphological and
functional) with histopathological response. Also, the dif-
ference in the utilized b values, MR scanners, acquisition
sequence used and the methods of ADC calculation (multi-
ple region of interest (ROI) for Sharma and single ROI for
our study) resulted in different calculated cut-off values
to define the responder status on the ADC basis (11).In the study by Belli et al., a 20% increase in ADC value
(post-NAC versus pre- NAC) was adopted as a cut off value,
to define the responder status on the basis of DWI
sequence and compared the DWI status findings with the
histopathologic response. This yielded an 80% sensitivity,
84% specificity, and 82% accuracy. Same data reported that
the morphological MRI imaging according to the RECIST
classification well evaluated the histologic response (sensi-
tivity 96%, specificity 73%, and diagnostic accuracy 84%)
(3).
In our study, the final DWI response (based on the 3STD
criterion) had a sensitivity of 68.8% and a specificity of
82.4% in predicting the pathological response, while the
morphological MR response (based on the RECIST crite-
rion) yielded a sensitivity and specificity of 87.5% and
76.5% respectively.
Fig. 1. A 39 years old female presenting with a hard huge mass occupying almost the entire left breast. (A) Pre NAC ADC map and CEMRI, (B) post 1st cycle
of NAC showing significant increase in ADC value with almost no change in size, (C) post 2nd cycle, the percentage increase in the ADC value as well as the
percentage reduction in the longest diameter indicates a good response, and (D) preoperative MRI showing no residual lesion in the DWI (right) consistent
with the pathological specimen of Pcr, however CEMRI (left) still shows a small enhancing lesion.
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Fig. 2. A 59 years old female presenting with a right inner breast mass. (A) Pre NAC CEMRI (left) and DWI (right) showing a heterogeneously enhancing
mass with corresponding bright signal in the DWI, (B) post 1st cycle of NAC CEMRI (top) and merge view between DWI & ADC map (bottom) showing
almost no change in size, with significant increase in ADC value predicting good response, (C) post 2nd cycle merge view between DWI and CEMRI (top) and
between DWI & ADC map(bottom) predicting good response in both CEMRI & DWI according to our calculated cut off values, and (D) preoperative MRI
showing no residual lesion in the CEMRI with a small enhancing lesion in the DWI which revealed to be hemorrhagic foci in the pathological specimen.
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Fig. 2 (continued)
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Patients (55) and measured ADC using b values of 0 and
800, both of which could justify the difference in the
reported sensitivities between our study and their study.
More importantly, in the latter study, the MR-assessed
tumor response was not compared with histopathological
response but to clinical response.
DW imaging correctly depicted the presence of resid-
ual disease in 26 out of 28 lesions, while CE MR depicted
a correct diagnosis in 24 of the 28 lesions giving a sensi-
tivity of 93% and 86%, respectively, for the detection of
non-residual cancer cases at the end of therapy. This
was in agreement with the study done by Woodhams
and coworkers (16).
The pathologic analysis from 2 cases (false-negative at
CE MR imaging but true-positive at DW imaging) showed
packed cancer cells. DW imaging was able to depict
residual diseases with high signal intensity because it is
sensitive to high cell density. The 2 false-negative cases
(on both DW images & CEMR Images) showed small mul-
tiple foci of DCIS, which were missed in both imaging
techniques. This could be explained by the low degree
of angiogenesis of DCIS as mentioned by Marson et al.
Meanwhile, the relatively low cellularity may be a con-
tributing factor for the failure of DWI to detect DCIS
(17,18).
According to Atlas et al., hematomas in the brain show
significantly reduced ADCs and demonstrated high signal
intensity on DW images. The presence of blood in pathol-
ogy specimen rationalized the single false positive case at
DWI in our study (19).The longest diameter of tumor measured by both CEMRI
and DWI at the end of chemotherapy significantly
(p < 0.001) correlated with the largest diameter of residual
tumor measured by pathology. Similar findings were
reported by Iacconi and their coworkers, who evaluated
the role of mean diffusivity as a predictive index of
the response to chemotherapy in 21 patients with LABC
(11).
The residual cancer was grossly underestimated in
diameter in one of the 2 true positive cases at DWI that
was false negative in CEMRI. The pathologic findings of
these cases showed diffuse cancer cells infiltrating the fat
tissue, which were not visualized at DW imaging. On the
other hand, CEMRI overestimated the residual disease in
one of the true positive cases at CEMRI and DWI, due to
enhancement of the fibrotic scar with viable tumor tissue
(see Figs. 1–3).5. Limitations
We had the following limitations with our study:
1. The small patients’ population in our study prevented
definitive conclusions.
2. Lack of consistency in the thresholds applied to DW
MRI parameters. Unlike for CEMRI measurements, there
are standardized response criteria for percentage reduc-
tions in uni- or bidimensional tumor size. Future stud-
ies should consider reporting accuracy at these
thresholds.
Fig. 3. A 60 years old female patient presented with a hard mass in the central quadrant of the right breast. (A) Pre NAC CEMRI (right) and ADC map (left)
showing a heterogeneously enhancing mass with corresponding dark signal in the ADC map, (B) post 1st cycle of NAC CEMRI (right) and ADC map (left)
showing mild reduction in size predicting poor response, with significant increase in ADC value falsely predicting good pathological response, (C) post 2nd
cycle, the percentage reduction in size was still in favor with poor response with further increase in the ADC which according to our calculated cut off values
predicts good response, and (D) preoperative MRI showing residual lesion in both the CEMRI (right) and the DWI (left) consistent with a non responder
patient to NAC. Longest diameter of residual lesion was 5.5 cm in CEMRI & 4.8 cm in DWI, The residual lesion was overestimated in the CE MRI due to
enhancement of the necrotic cells together with viable cells.
1730 H. El Kassas et al. / The Egyptian Journal of Radiology and Nuclear Medicine 47 (2016) 1721–17323. The accuracy of CEMRI and DW measurements may
become difficult to assess tumors with linear/dendritic
neoplastic distribution and multicentricity with lesions
smaller than resolution of MD map, although this was
not experienced in our study.4. Definitions of pCR are not standardized, varying in the
inclusion or exclusion of response in the axillary nodes,
and the presence or absence of residual DCIS could
plausibly affect test performance.
Fig. 3 (continued)
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was performed for cases with complete clinical or radi-
ological response; thus, it is possible that residual can-
cers were missed at surgery, leading to improper
assessment of the residual lesion.
6. Conclusion
In pathological responders, an increase in ADC values in
DW MRI, was noted as early as after the first cycle of ther-
apy; whereas changes in structural parameters; longest
diameter, were evident only after the second cycle. Also
early during the course of treatment, changes in ADC had
a better predictive index with high accuracy in correlation
with the pathological response; while changes in the long-
est diameter serve as a better tool starting from the second
cycle of NAC.
Both CE MRI and DW MRI were well able to detect
residual disease when correlated with the final pathology.
The accuracy of DW MRI, in detecting residual lesions, was
as accurate as CE MRI, making it a valuable tool in patients
in whom contrast material is contraindicated.Conflict of interest
The authors declare that there is no conflict of interest.
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